Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5 [Benefici del paracalcitolo iniettabile sulla morbilita cardiaca indotta da insufficienza renale in soggetti con nefropatia cronica di stadio 5]

Trial Profile

Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5 [Benefici del paracalcitolo iniettabile sulla morbilita cardiaca indotta da insufficienza renale in soggetti con nefropatia cronica di stadio 5]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2013

At a glance

  • Drugs Paricalcitol (Primary)
  • Indications Kidney disorders
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Registrational
  • Acronyms PRIMO-II
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 27 Feb 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top